Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne

Melinta Therapeutics, Inc. a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that the company’s partner has initiated a Phase 2 clinical study of topical radezolid for the treatment of mild-to-moderate acne vulgaris.

Read the full press releaseCompany website